CK‐18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission

Incomplete histological remission of autoimmune hepatitis (AIH) is associated with a reduced long‐term survival and an increased relapse rate even during biochemical remission (BR). The aim of this international multicentre study was to explore the diagnostic fidelity of cytokeratin‐18 cell death ma...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2021-01, Vol.41 (1), p.123-127
Main Authors: Derben, Finn C., Engel, Bastian, Zachou, Kalliopi, Hartl, Johannes, Hartleben, Björn, Bantel, Heike, Schramm, Christoph, Dalekos, George N., Manns, Michael P., Jaeckel, Elmar, Taubert, Richard
Format: Article
Language:English
Subjects:
Apoptosis
Cell death
Cytokeratin
cytokeratin‐18
Diagnostic systems
Hepatitis
Immunoglobulins
M30
M65
Markers
Mortality
Remission
therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Incomplete histological remission of autoimmune hepatitis (AIH) is associated with a reduced long‐term survival and an increased relapse rate even during biochemical remission (BR). The aim of this international multicentre study was to explore the diagnostic fidelity of cytokeratin‐18 cell death markers to noninvasively detect incomplete histological remission. Thereby, cytokeratin‐18 cell death marker M65 but not ALT and immunoglobulins was significantly higher in patients with incomplete histological remission (mHAI ≥ 4) compared to those with mHAI ≤ 3. M65 levels > 305 U/L, identified in the training cohort, facilitated the noninvasive detection of incomplete histological remission with a sensitivity of 75% and negative predictive value of 86% in the validation cohort. While BR with M65  305 U/L reduced the rate of histological remission to 60%. In conclusion, M65 may help to better select patients for or to reduce surveillance liver biopsies in the future.
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.14699